[go: up one dir, main page]

TR201009394A2 - Geliştirilmiş montelukast formülasyonları. - Google Patents

Geliştirilmiş montelukast formülasyonları.

Info

Publication number
TR201009394A2
TR201009394A2 TR2010/09394A TR201009394A TR201009394A2 TR 201009394 A2 TR201009394 A2 TR 201009394A2 TR 2010/09394 A TR2010/09394 A TR 2010/09394A TR 201009394 A TR201009394 A TR 201009394A TR 201009394 A2 TR201009394 A2 TR 201009394A2
Authority
TR
Turkey
Prior art keywords
improved
montelukast
formulations
montelukast formulations
counteract
Prior art date
Application number
TR2010/09394A
Other languages
English (en)
Inventor
Bi̇lgi̇ç Mahmut
Original Assignee
Bi̇lgi̇ç Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bi̇lgi̇ç Mahmut filed Critical Bi̇lgi̇ç Mahmut
Priority to TR2010/09394A priority Critical patent/TR201009394A2/tr
Priority to PCT/TR2011/000244 priority patent/WO2012064302A2/en
Priority to PCT/TR2011/000245 priority patent/WO2012064303A2/en
Priority to PCT/TR2011/000246 priority patent/WO2012064304A2/en
Publication of TR201009394A2 publication Critical patent/TR201009394A2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/2036—Silicones; Polysiloxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Mevcut buluş, montelukast ve/veya farmasötik kabul edilebilir bir tuzunu içeren formülasyonlarında kullanılan yardımcı maddelerin etken madde üzerindeki olumsuz etkilerini gidermek üzere tasarlanmış bileşimlerle ilgilidir.
TR2010/09394A 2010-11-11 2010-11-11 Geliştirilmiş montelukast formülasyonları. TR201009394A2 (tr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
TR2010/09394A TR201009394A2 (tr) 2010-11-11 2010-11-11 Geliştirilmiş montelukast formülasyonları.
PCT/TR2011/000244 WO2012064302A2 (en) 2010-11-11 2011-11-03 Improved montelukast formulations
PCT/TR2011/000245 WO2012064303A2 (en) 2010-11-11 2011-11-03 Improved montelukast combinations
PCT/TR2011/000246 WO2012064304A2 (en) 2010-11-11 2011-11-03 Combinations comprising montelukast

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2010/09394A TR201009394A2 (tr) 2010-11-11 2010-11-11 Geliştirilmiş montelukast formülasyonları.

Publications (1)

Publication Number Publication Date
TR201009394A2 true TR201009394A2 (tr) 2012-06-21

Family

ID=45464073

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2010/09394A TR201009394A2 (tr) 2010-11-11 2010-11-11 Geliştirilmiş montelukast formülasyonları.

Country Status (2)

Country Link
TR (1) TR201009394A2 (tr)
WO (3) WO2012064302A2 (tr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2677649C2 (ru) * 2013-02-21 2019-01-18 Глэнмарк Фармасьютикалс Лимитед Фармацевтические композиции монтелукаста и левоцетиризина
KR102226833B1 (ko) * 2013-06-28 2021-03-12 한미약품 주식회사 레보세티리진 및 몬테루카스트를 포함하는 안정성이 개선된 복합 과립 제형
CN104666302B (zh) * 2013-11-27 2017-06-30 北京韩美药品有限公司 组合物及其制备方法、口服液及其制备方法
CN103655497B (zh) * 2013-12-18 2018-05-29 北京华禧联合科技发展有限公司 一种孟鲁司特钠口腔崩解片及其制备方法
CN104840427B (zh) * 2014-02-13 2017-09-29 长春海悦药业股份有限公司 一种含有孟鲁司特钠的药物组合物
EP2949321A1 (en) * 2014-05-26 2015-12-02 Sanovel Ilac Sanayi ve Ticaret A.S. Multilayer formulations of fexofenadine and montelukast
CN117562863B (zh) * 2023-12-14 2025-07-25 毕节市第一人民医院 一种孟鲁司特钠咀嚼片及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE165088T1 (de) 1990-10-12 1998-05-15 Merck Frosst Canada Inc Ungesättigte hydroxyalkylchinolinsäuren als leukotrien-antagonisten
WO2007092031A1 (en) * 2006-02-09 2007-08-16 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical formulations of montelukast sodium
WO2009122187A2 (en) * 2008-04-03 2009-10-08 Cipla Limited Pharmaceutical composition
TR200806298A2 (tr) * 2008-08-22 2010-03-22 Bi̇lgi̇ç Mahmut Farmasötik formülasyon
WO2010041277A2 (en) 2008-10-06 2010-04-15 Jubilant Organosys Limited Stable pharmaceutical compositions of montelukast or its salts or solvates or hydrates
WO2010107404A1 (en) * 2009-03-16 2010-09-23 Mahmut Bilgic Stable pharmaceutical combinations

Also Published As

Publication number Publication date
WO2012064304A2 (en) 2012-05-18
WO2012064304A3 (en) 2012-08-09
WO2012064303A3 (en) 2012-07-19
WO2012064303A2 (en) 2012-05-18
WO2012064302A2 (en) 2012-05-18
WO2012064302A3 (en) 2012-07-19

Similar Documents

Publication Publication Date Title
MX348823B (es) Formulaciones estables de linaclotida.
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
EA201201263A1 (ru) Фармацевтическая композиция, содержащая этексилат дабигатрана
MX2015017964A (es) Inhibidores de bromodominio.
UA109010C2 (en) Morpholino pyrividines and their use in therapy
EA201401351A1 (ru) Производные бензимидазол-пролина
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
EA201190145A1 (ru) Фармацевтические композиции, содержащие основание прасугреля или его фармацевтически приемлемые соли присоединения кислоты, и способы их приготовления
EA201201050A1 (ru) Пиразолы в качестве антагонистов crth2
EA201390662A1 (ru) Фармацевтическая композиция, содержащая дутастерид
TR201009394A2 (tr) Geliştirilmiş montelukast formülasyonları.
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
EA201400822A1 (ru) Производные гетероциклических амидов в качестве антагонистов p2xрецептора
UA115357C2 (uk) Похідні піридин-4-ілу
EA201300034A1 (ru) Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения
MX2016001422A (es) Composicion farmaceutica de fingolimod.
EA201492029A1 (ru) N-этил-4-гидроксил-1-метил-5-(метил(2,3,4,5,6-пентагидроксигексил)амино)-2-оксо-n-фенил-1,2-дигидрохинолин-3-карбоксамид
EA201300857A1 (ru) Пиразолы в качестве антагонистов crth2
UA109804C2 (xx) 2-метоксипіридин-4-ільні похідні
EP2611799A4 (en) PHARMACEUTICAL COMPOSITIONS OF LINEZOLID
TR201803451T4 (tr) Olmesartan formülasyonlari.
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
TR201009399A2 (tr) Hızlı çözünen efervesan rosuvastatin formülasyonları.
TR201007926A1 (tr) Prasugrel tablet formülasyonları.